Pure Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.64M Buy
3,310
+404
+14% +$179K 0.02% 198
2026
Q1
$1.3M Sell
2,906
-204
-7% -$95.1K 0.02% 197
2025
Q4
$1.41M Sell
3,110
-220
-7% -$94.8K 0.02% 190
2025
Q3
$1.3M Buy
3,330
+439
+15% +$183K 0.02% 183
2025
Q2
$1.29M Buy
2,891
+2,062
+249% +$950K 0.02% 182
2025
Q1
$402K Buy
829
+248
+43% +$116K 0.01% 270
2024
Q4
$234K Buy
581
+21
+4% +$9.73K 0.01% 314
2024
Q3
$261K Buy
560
+2
+0.4% +$961 0.01% 290
2024
Q2
$261K Buy
558
+25
+5% +$10.9K 0.01% 277
2024
Q1
$223K Buy
+533
New +$225K 0.01% 288

Other funds holding VRTX

Pure Financial Advisors's VRTX Position: Q2 2026 in Review

Pure Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $179K and bringing the position to 3,310 shares worth $1.64M. The position accounts for 0.02% of the portfolio, ranked #198.

Pure Financial Advisors first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Pure Financial Advisors held 3,310 shares of Vertex Pharmaceuticals worth $1.64M as of Q2 2026.
  • Pure Financial Advisors bought 404 Vertex Pharmaceuticals shares in Q2 2026, an estimated $179K.
  • Vertex Pharmaceuticals made up 0.02% of Pure Financial Advisors's portfolio in Q2 2026, its #198 holding.
  • Pure Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.